Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 2016 (1), 698-706

Second-line Therapies in Immune Thrombocytopenia


Second-line Therapies in Immune Thrombocytopenia

Rachael F Grace et al. Hematology Am Soc Hematol Educ Program.


Immune thrombocytopenia (ITP) is a rare, acquired autoimmune condition characterized by a low platelet count and an increased risk of bleeding. Although many children and adults with ITP will not need therapy beyond historic first-line treatments of observation, steroids, intravenous immunoglobulin (IVIG), and anti-D globulin, others will have an indication for second-line treatment. Selecting a second-line therapy depends on the reason for treatment, which can vary from bleeding to implications for health-related quality of life (HRQoL) to likelihood of remission and patient preference with regard to adverse effects, route of administration, and cost. Published studies of these treatments are limited by lack of comparative trials, in addition to inconsistent outcome measures, definitions, and efficacy endpoints. This article provides an up-to-date comparison of the second-line treatments, highlighting important outcome measures including bleeding, HRQoL, fatigue, and platelet counts, which influence treatment selection in a shared decision-making model.

Conflict of interest statement

Conflict-of-interest disclosures: R.F.G. has received research funding from Agios Pharmaceuticals. C.N. declares no competing financial interests.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

MeSH terms